Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Depreciation & Amortization (CF) (2017 - 2025)

Historic Depreciation & Amortization (CF) for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $110000.0.

  • Aclaris Therapeutics' Depreciation & Amortization (CF) fell 3854.75% to $110000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $495000.0, marking a year-over-year decrease of 4450.67%. This contributed to the annual value of $807000.0 for FY2024, which is 648.9% down from last year.
  • Aclaris Therapeutics' Depreciation & Amortization (CF) amounted to $110000.0 in Q3 2025, which was down 3854.75% from $114000.0 recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Depreciation & Amortization (CF) registered a high of $288000.0 during Q1 2021, and its lowest value of $110000.0 during Q3 2025.
  • Over the past 5 years, Aclaris Therapeutics' median Depreciation & Amortization (CF) value was $198000.0 (recorded in 2023), while the average stood at $196947.4.
  • Over the last 5 years, Aclaris Therapeutics' Depreciation & Amortization (CF) had its largest YoY gain of 14387.53% in 2021, and its largest YoY loss of 6768.19% in 2021.
  • Quarter analysis of 5 years shows Aclaris Therapeutics' Depreciation & Amortization (CF) stood at $197000.0 in 2021, then decreased by 3.55% to $190000.0 in 2022, then rose by 20.0% to $228000.0 in 2023, then plummeted by 37.28% to $143000.0 in 2024, then dropped by 23.08% to $110000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $110000.0 for Q3 2025, versus $114000.0 for Q2 2025 and $128000.0 for Q1 2025.